Omeros Corporation $OMER Shares Sold by Ancora Advisors LLC

Ancora Advisors LLC decreased its position in Omeros Corporation (NASDAQ:OMER - Free Report) by 93.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,800 shares of the biopharmaceutical company's stock after selling 80,000 shares during the period. Ancora Advisors LLC's holdings in Omeros were worth $48,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Trexquant Investment LP purchased a new stake in Omeros during the first quarter worth about $88,000. Hsbc Holdings PLC purchased a new stake in Omeros during the first quarter worth about $142,000. Wellington Management Group LLP purchased a new stake in Omeros during the first quarter worth about $1,118,000. Nuveen LLC purchased a new stake in Omeros during the first quarter worth about $938,000. Finally, Invesco Ltd. boosted its holdings in Omeros by 169.1% during the first quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company's stock worth $716,000 after buying an additional 54,696 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company's stock.

Omeros Price Performance

Shares of NASDAQ OMER traded up $0.01 on Wednesday, hitting $4.27. The company's stock had a trading volume of 901,537 shares, compared to its average volume of 901,534. Omeros Corporation has a 12-month low of $2.95 and a 12-month high of $13.60. The company has a market capitalization of $290.60 million, a price-to-earnings ratio of -2.02 and a beta of 2.37. The stock has a 50 day moving average of $3.90 and a 200-day moving average of $5.21.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.02. The business had revenue of $28.60 million during the quarter, compared to analysts' expectations of $0.31 million. Sell-side analysts expect that Omeros Corporation will post -3.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Wall Street Zen downgraded shares of Omeros from a "hold" rating to a "sell" rating in a report on Friday, June 27th. D. Boral Capital reissued a "buy" rating and set a $36.00 price objective on shares of Omeros in a report on Wednesday, September 3rd. HC Wainwright reissued a "buy" rating and set a $9.00 price objective on shares of Omeros in a report on Friday, June 27th. Finally, Needham & Company LLC restated a "hold" rating on shares of Omeros in a report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Omeros has an average rating of "Moderate Buy" and a consensus target price of $18.00.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.